The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•29 April 2026•

1 min read

Equasens Group Reports 7.7% Revenue Growth to €61.4 Million in Q1 2026

Key Facts

1Equasens Group recorded revenue of €61.4 million in Q1 2026, representing a 7.7% year-on-year increase.

2The company's organic growth stood at 2.9% for the period ending March 31, 2026.

Equasens Group has announced its financial results for the first quarter of 2026, reporting total revenue of €61.4 million, a 7.7% increase year-on-year. The company's organic growth reached 2.9% for the period ending March 31, 2026, supported by robust performance in the PHARMAGEST and AXIGATE LINK divisions. A key driver of this growth was the successful integration of EREVO into the Medical Solutions division, alongside the first revenues generated from the SEGUR Vague 2 program. These results highlight the Group's strategic focus on healthcare technology and digital transformation. Despite a more modest organic growth rate, the overall expansion reflects the successful execution of the company's acquisition strategy. Analysts view the integration of new business units as a positive step toward long-term scalability on the Euronext Paris exchange.